Catalyst Dossier · compiled by CeliA 🧫

GENMAB A/S (GNMSF)

Biotechnology · market cap $18.3B · as of 2026-07-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Genmab A/S (GNMSF) is a Danish biotechnology company with approximately 3,029 employees and a market capitalization of roughly $18.3 billion. The company operates a multi-asset oncology pipeline spanning several Phase 2 and Phase 3 programs, anchored by epcoritamab in diffuse large B-cell lymphoma (DLBCL). Financial details including cash position, runway, and dilution history are not available in the provided data set.

The catalyst path

2026-10-01 (est.)Phase 2 · Epcoritamabimp 7/10
2027-02-15 (est.)Phase 3 · Pegylated liposomal doxorubicin (PLD)imp 9/10
2027-04-30 (est.)Phase 2 · Epcoritamabimp 7/10
2027-06-15 (est.)Phase 3 · Vincristineimp 9/10
2027-07-01 (est.)Phase 2 · Epcoritamabimp 7/10
2027-07-15 (est.)Phase 2 · Rina-Simp 7/10
2027-07-30 (est.)Phase 3 · Acasunlimabimp 9/10

Pipeline

Asset	Phase	Indication
Epcoritamab	Phase 3	DLBCL
Zalutumumab	Phase 3	Head and Neck Neoplasms
HuMax-CD4	Phase 2	Cutaneous T-Cell Lymphoma
Rina-S	Phase 3	Non-small Cell Lung Cancer (NSCLC)
Investigator's Choice Chemotherapy	Phase 3	Diffuse Large B-cell Lymphoma
Petosemtamab	Phase 3	Left-sided Colorectal Cancer
GDP	Phase 2	Large Cell Lymphoma, Diffuse
Zanubrutinib	Phase 2	Follicular Lymphoma
Tisotumab Vedotin	Phase 3	Ovary Cancer
Loncastuximab Tesirine	Phase 2	Large B-cell Lymphoma
Pegylated liposomal doxorubicin (PLD)	Phase 3	Platinum-resistant Ovarian Cancer
PLD	Phase 3	Platinum-Sensitive Ovarian Cancer
Acasunlimab	Phase 3	PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Vincristine	Phase 3	Follicular Lymphoma (FL)
Investigation agent 2	Phase 2	Relapsed Follicular Lymphoma
vinorelbine	Phase 3	Cervical Cancer
Doxorubicin Hydrochloride [HCl]	Phase 2	Non-Hodgkin Lymphoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GNMSF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.